Clinical Trials in Maryland

Showing 3021-3040 of 19,983 trials

Study of the CycloPen Micro-Interventional System and Long-Term Clinical Outcomes

NCT05506423

This observational study will enroll adults with open angle glaucoma (OAG) who had surgery to reduce intraocular pressure (IOP) using the CycloPen Micro-Interventional System. Consenting participants will be followed for 24 months after their surgery. Data regarding IOP, use of glaucoma medications, and any side effects related to the surgery will be collected from participants' preoperative examination, their surgery, and postoperative examinations.

Open Angle Glaucoma

Iantrek, Inc.300 participantsStarted Aug 2022

Newport Beach, California, United States • Cape Coral, Florida, United States • DeLand, Florida, United States +13 more locations

Active Not RecruitingPhase 217 miles

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

NCT02864992

This study looked at how effective the study drug (tepotinib) was at stopping the growth and spread of lung cancer. This study also measures a number of other things including safety of the study drug and the side effects, how body processes the study drug, or how the study drug affects your quality of life. The study also has an optional pharmacogenetic research part. Pharmacogenetic research is an important way to try to understand the role of genetics in human disease and how genes impact the effectiveness of drugs, because differences in genes can change the way a person responds to a particular drug.

Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET AmplificationLung Adenocarcinoma Stage IIIB/IV

EMD Serono Research & Development Institute, Inc.337 participantsStarted Sep 2016

Duarte, California, United States • Encinitas, California, United States • Orange, California, United States +173 more locations

Study of the CycloPen Micro-Interventional System and Long-Term Clinical Outcomes

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

Find Trials by Condition in Maryland

A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B

Adolescent Vaping Characterization and Parent Views on Adolescent Vaping Protocol

Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

Suvorexant for Opioid/Stimulant Co-use

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer

A Prospective Non-concurrent Controlled Evaluation of Open and MAS® PLIF

Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A

Ribociclib and Letrozole Treatment in Ovarian Cancer

Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD

SP Thoracic IDE Study

SpineTRACK Registry - Spinal Outcomes Registry

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)

A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors